Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
InventisBio Co., Ltd
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
Histological or cytological confirmation diagnosis of Non Small Cell Lung Cancer (NSCLC).
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI e.g. gefitinib or erlotinib. In addition other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
Confirmation that the tumour harbours an EGFR T790M mutation.
No deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.
Evaluable or measurable disease per RECIST v1.1
You may not be if
Treatment with an EGFR TKI (erlotinib or gefitinib) within 14 days of the first dose of study treatment.
Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
